HIF-PH inhibitors activate HIF signaling, which enhances iron absorption and utilization through the hepcidin–ferroportin axis [24], with recent studies showing decreased hepcidin levels post-therapy in heart failure patients [25]. The gene discussed is SLC40A1; the disease is heart failure.